Any current/future new fundraising through debt or equity?

There is no explicit mention of any new fundraising through debt or equity planned for FY27. The company noted ongoing investments and capacity expansions are largely targeted and planned (e.g., Lexington expansion). Debt level currently operates around a net debt-to-EBITDA ratio of 3.6x, expected to remain range-bound in FY27. The company aims to reduce net debt-to-EBITDA to around 1x over the long term but expects elevated levels in the near term due to capex. No mention of equity fundraising; capex for FY27 is estimated at INR 120-135 million, excluding acquisitions like Kenalog. The compan

Any current/future capex/capital investment/strategic investment?

The Lexington expansion is ongoing with expected completion in the latter half of calendar year 2027. The Riverview expansion is largely complete and already serving clients. Capex for FY27 is projected at INR 120 million to INR 135 million, largely towards the Lexington expansion. No new significant capex plans were indicated beyond these projects, suggesting a period of consolidation. Customer-funded capex related to a specific suite is complete; no further spend planned there. Future capex excludes amounts spent on the Kenalog acquisition or potential similar deals. The company is prioritiz

Future growth expectations in sales/revenue/volumes?

FY27 revenue growth expected in the early to mid-teens percentage range across all businesses. CDMO business growth anticipated to be healthy due to improved biotech funding, increased RFPs, higher win rates, and a strong pipeline of RFPs at overseas sites. CDMO revenue will remain back-weighted to the second half, especially Q4, due to client order timings. On-patent commercial manufacturing revenue grew nearly 50% from the prior year, with 15–16 products supplied; expected continued growth with new product launches. ADC (Antibody-Drug Conjugates) segment poised to be a meaningful growth driv

Future growth expectations in earnings/operating earnings/profits/EPS?

For FY27, Piramal Pharma expects early to mid-teens revenue growth across all businesses. EBITDA and PAT are projected to grow faster than revenue in FY27. The CDMO business will continue to be back-weighted to H2, particularly Q4, due to client delivery timings. Operating margins are expected to improve as scale increases, with tax rates normalizing around 24-25%. Long-term net debt-to-EBITDA target is approximately 1, though it remains elevated in the short term due to ongoing capital investments. Growth drivers include expansion of overseas sites, differentiated specialty products, and mome

Current/ Expected Orderbook/ Pending Orders?

Piramal Pharma is seeing a strong pipeline of Requests for Proposals (RFPs) at overseas sites, which, if converted, will help scale revenues and improve operating leverage. The company has improved RFP-to-order conversion rates, especially with new customers. A healthy order book for FY27 and beyond is expected, which is crucial for medium-term growth. They are working on over 155 molecules in development, with 25 in Phase III, representing future on-patent commercial manufacturing opportunities. CDMO business revenues were INR 1,708 crores in Q4 FY26 and INR 4,915 crores for the full year, wi

IN US

Sale is live|00:00:00left today

Piramal Pharma LtdQ1 FY26Pharmaceuticals & Biotechnology

Piramal Pharma Ltd Q1 FY26 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹164Market Cap: ₹23.2K CrSector: Pharmaceuticals & Biotechnology

Management growth scorecard

Revenue

Category 3

Margin

Category 3

Fundraise

Yes

Order

Yes

Capex

Yes

3 of 5 growth signals are positive.

Full analysis

Revenue guidance

Category 3

→FY27 revenue growth expected in the early to mid-teens percentage range across all businesses.
→CDMO business growth anticipated to be healthy due to improved biotech funding, increased RFPs, higher win rates, and a strong pipeline of RFPs at overseas sites.
→CDMO revenue will remain back-weighted to the second half, especially Q4, due to client order timings.
→On-patent commercial manufacturing revenue grew nearly 50% from the prior year, with 15–16 products supplied; expected continued growth with new product launches.
→ADC (Antibody-Drug Conjugates) segment poised to be a meaningful growth driver in FY27-FY28 and beyond with new customers added.
→Consumer Health Care business grew 17% in FY26 and expects continued broad-based growth with premiumization and strategic launches.
→API generics business expected to grow modestly, supported by new products and expanded market presence.
→Overall, emphasis on sustainable, profitable growth with operating leverage expected to drive faster EBITDA growth than revenue.

Margin guidance

Category 3

→For FY27, Piramal Pharma expects early to mid-teens revenue growth across all businesses.
→EBITDA and PAT are projected to grow faster than revenue in FY27.
→The CDMO business will continue to be back-weighted to H2, particularly Q4, due to client delivery timings.
→Operating margins are expected to improve as scale increases, with tax rates normalizing around 24-25%.
→Long-term net debt-to-EBITDA target is approximately 1, though it remains elevated in the short term due to ongoing capital investments.
→Growth drivers include expansion of overseas sites, differentiated specialty products, and momentum in consumer healthcare power brands and e-commerce.
→Exceptional charges like intangible asset impairment in FY26 are not expected to recur regularly, with stricter capex prioritization in place.
→Overall, management expresses confidence in returning to consistent and profitable growth in FY27 and beyond.

3 more insights locked — sign up free to unlock

Fundraise plans

Yes

→There is no explicit mention of any new fundraising through debt or equity planned for FY27.
→The company noted ongoing investments and capacity expansions are largely targeted and planned (e.g., Lexington expansion).
→Debt level currently operates around a net debt-to-EBITDA ratio of 3.6x, expected to remain range-bound in FY27.
→The company aims to reduce net debt-to-EBITDA to around 1x over the long term but expects elevated levels in the near term due to capex.
→No mention of equity fundraising; capex for FY27 is estimated at INR 120-135 million, excluding acquisitions like Kenalog.
→The company is managing working capital carefully to support cash flow and debt servicing.
→Exceptional intangible asset impairment suggests prioritizing capital allocation but no direct references to raising funds.

Order book

Yes

→Piramal Pharma is seeing a strong pipeline of Requests for Proposals (RFPs) at overseas sites, which, if converted, will help scale revenues and improve operating leverage.
→The company has improved RFP-to-order conversion rates, especially with new customers.
→A healthy order book for FY27 and beyond is expected, which is crucial for medium-term growth.
→They are working on over 155 molecules in development, with 25 in Phase III, representing future on-patent commercial manufacturing opportunities.
→CDMO business revenues were INR 1,708 crores in Q4 FY26 and INR 4,915 crores for the full year, with modest growth adjusted for temporary de-stocking.
→Growth was slower in H1 due to subdued biopharma funding but rebounded strongly in H2, accelerating order inflows.

Capex plans

Yes

→The Lexington expansion is ongoing with expected completion in the latter half of calendar year 2027.
→The Riverview expansion is largely complete and already serving clients.
→Capex for FY27 is projected at INR 120 million to INR 135 million, largely towards the Lexington expansion.
→No new significant capex plans were indicated beyond these projects, suggesting a period of consolidation.
→Customer-funded capex related to a specific suite is complete; no further spend planned there.
→Future capex excludes amounts spent on the Kenalog acquisition or potential similar deals.
→The company is prioritizing capital allocation to areas with anticipated returns, reflected in a recent impairment of certain intangible assets.

How does Piramal Pharma Ltd rank vs peers in Pharmaceuticals & Biotechnology?

Pro feature

1Piramal Pharma Ltd

Rev 3Mar 3

See full Pharmaceuticals & Biotechnology sector rankings

Want more stocks like Piramal Pharma Ltd?

Build an AI portfolio filtered by sector, market cap, and growth rank. Takes 2 minutes.

Build my portfolio